title: Low-dose foscarnet preemptive therapy for cytomegalovirus viremia after haploidentical bone marrow transplantation.
authors.forename: Hengxiang
authors.initials: H
authors.lastname: Wang
authors.forename: Ling
authors.initials: L
authors.lastname: Zhu
authors.forename: Mei
authors.initials: M
authors.lastname: Xue
authors.forename: Jing
authors.initials: J
authors.lastname: Liu
authors.forename: Zikuan
authors.initials: Z
authors.lastname: Guo
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016026:Bone Marrow Transplantation; D003587:Cytomegalovirus; D003586:Cytomegalovirus Infections / Q000097:blood / Q000517:prevention & control*; D005260:Female; D017245:Foscarnet / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D010750:Phosphoproteins / Q000097:blood; D014184:Transplantation, Homologous; D014763:Viral Matrix Proteins / Q000097:blood; D014766:Viremia / Q000097:blood / Q000517:prevention & control*
chemical_list: D000998:Antiviral Agents; D010750:Phosphoproteins; D014763:Viral Matrix Proteins; C464963:pp67 protein, human cytomegalovirus; D017245:Foscarnet